

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-236US

In Re Application Of: **SALMAN et al.**

JUL 13 2007

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/510,362	05/25/2005	TBA	26,815	1624	

Title: **alpha,omega--DICARBOXIMIDE DERIVATIVES AS USEFUL URO-SELECTIVE alpha1A ADRENOCEPTOR BLOCKERS**

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-236US

In Re Application of: *G. SALMAN et al.*

JUL 13 2007

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/510,362 TRADEMARK OFFICE	05/25/2005	TBA	26,815	1624	

Title: alpha,omega--DICARBOXIMIDE DERIVATIVES AS USEFUL URO-SELECTIVE alpha1A ADRENOCEPTOR BLOCKERS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.
 - Charge the amount of _____
 - Credit any overpayment.
 - Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

July 10, 2007

(Date)

Susan Dolci

Signature of Person Mailing Correspondence

Susan Dolci

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

G. E. Heibel
Signature

Dated: July 10, 2007

George E. Heibel
Reg. No. 42,648
Customer No. 26,815

CC:

INFORMATION DISCLOSURE CITATION

JUL 13 2007

SUPPLEMENTAL

Docket No.: RLL-236US

Serial No.: 10/510,362

Applicants: SALMAN et al.

Filed: 10/5/2004

Group:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	S1B1	EP 0 082 402	6/29/1983	EPO	C07D	491/18	
	S1B2	EP 0 109 562	5/30/1984	EPO	C07D	403/12	
	S1B3	FR 2 154 449	5/11/1973	France	C07D	233/72	EQUIVALENT GB 1 368 256
	S1B4	WO 00/04012	1/27/2000	PCT	C07D	401/06	
	S1B5	WO 01/05765	1/25/2001	PCT	C07D	211/88	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

s1C1	Takeo et al, "The Effects of a Novel Cyclohexane Dicarboximide Derivative, ST-6, on Hypoxia/Reoxygenation Injury in Perfused Rat Heart", <i>Biological & Pharmaceutical Bulletin (of Japan)</i> , 23(6):712-716 (2000)
s1C2	Paluchowska et al, "On the Bioactive Conformation of NAN-190 (1) and MP3022 (2), 5-HT _{1A} Receptor Antagonists," <i>Journal of Medicinal Chemistry</i> , 42(24):4952-4960 (1999)
s1C3	Wu et al, "Psychosedative Agents. N-(4-Phenyl-1-piperazinylalkyl)-Substituted Cyclic Imides," <i>Journal of Medicinal Chemistry</i> , 12:876-881 (1969)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.